(Q40667581)

22 September 2017

1 reference

title

Early empiric antibiotic therapy for febrile neutropenia patients at low risk (English)

1 reference

22 September 2017

Rolston KV

1

1 reference

PubMed ID

8803619

22 September 2017

Rubenstein EB

series ordinal

2

1 reference

PubMed ID

8803619

22 September 2017

Freifeld A

series ordinal

3

1 reference

22 September 2017

1 June 1996

1 reference

Infectious Disease Clinics of North America

22 September 2017

1 reference

22 September 2017

10

1 reference

22 September 2017

2

1 reference

22 September 2017

223-237

1 reference

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Overview of the problem of infections in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Beta-lactam regimens for the febrile neutropenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Colony-stimulating factors and neutropenia: intersection of data and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Home treatment of febrile neutropenia: an empirical oral antibiotic regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Aztreonam therapy in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Outpatient management of febrile episodes in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Controversies in the management of febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970297-X

7 January 2021

10.1016/S0891-5520(05)70297-X

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

8803619